A new landmark £2.3m NIHR-funded clinical trial called PARROT has launched in the UK. It is a joint UK and Australia clinical trial, led in the UK by researchers from the Alder Hey Children’s NHS Foundation Trust and the University of Liverpool.
Background
In the UK, there are large numbers of children with neurological impairments caused by conditions such as cerebral palsy and Down Syndrome. Many are prone to chest infections which can result in prolonged stays in hospital and even premature death.
Despite their impact on children, their families and health services, there is very little information on how best to prevent these repeated chest infections. Some doctors prescribe long-term antibiotics but we don’t really know whether this treatment makes any difference or not.
About the trial
PARROT is the largest ever trial involving this group of children and aims to recruit 500 children and young people aged 3-17 years with neurological impairment who are at risk of repeated chest infections. Each participant will be involved for a maximum of 20 months. Participants will be split into two groups, one will receive an antibiotic called azithromycin and the other control group will receive a placebo.
PARROT aims to find out whether a 12-month treatment with azithromycin affects rates of hospital visits, infections, GP and A&E visits, prescriptions, the treatment of infections, and quality of life of both parent and child. To make it easier for families, follow-up assessments can be done remotely so families can complete study questionnaires at home and collect respiratory swabs themselves.
The trial is being coordinated by the Liverpool Clinical Trials Centre.
More information on the trial and how to participateA map of hospitals participating in the trial can be found under the ‘sites’ tab.
Benefitting patients
Julia Melluish is a parent of 15 year old twin boys one of who has cerebral palsy, Julia says: “It’s been a real privilege to be involved in designing the PARROT trial. Repeated admissions to hospital for respiratory infections is a vitally important issue for many families like mine. As an established member of the PenCRU Family Faculty at the University of Exeter Medical School I know my experience as a parent carer is valued, respected, and appreciated. I feel the opinions of all the parent carers in the group have been heard by the research team and made a fundamental difference to the way the trial has been put together in terms of expectations on participants and the way the outcomes will be measured. The results of this trial could potentially lead to huge cost savings for the NHS and significantly improve the quality of life and chest health of vulnerable neurologically impaired children and young people. So we hope lots of families will want to, and feel able to, take part.”
‘’This study is important to me because my son has been in and out of the hospital in the past couple of months with chest infections. I’m hoping this research will help him in the future’’.
Nawal, mum of Majd
Hayley, the mum of Holly, says: “I have championed the Parrot trial as a parent carer. It has enormous potential to add to the lives of children like my daughter Holly. Holly had complex health needs which meant managing a range of conditions, but especially her chest. She spent lots of time in the hospital. PARROT will hopefully provide evidence to help doctors decide on how best to manage chest infections in children like Holly.”
The trial is funded by both the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) (£2.3m) and Australia’s National Health and Medical Research Council (NHMRC) ($1.4million).
The following are collaborators on the PARROT trial:- Alder Hey Children’s NHS Foundation Trust, University of Liverpool, University of Newcastle Upon Tyne, University of Exeter, Bangor University, Queen Mary University of London, Menzies School of Health Research, Murdoch Children’s Research Institute, Guy’s and St Thomas’s NHS Foundation Trust and University College London.